Published March 22, 2026 | Last Updated September 20, 2026

Progress, Accountability, and the Future of Blood Policy

The Jehovah’s Witness blood policy changed significantly on March 20, 2026, when the Governing Body announced a major revision to its long-standing medical guidance concerning blood. In Governing Body Update #2, the organization reclassified the medical use of a patient’s own blood—including preoperative autologous donation (PAD), in which blood is collected, stored, and later reinfused—from a prohibited practice to a matter of individual conscience.¹ At that time, however, transfusion of red blood cells, white blood cells, platelets, and plasma from another person remained prohibited.

Six months later, on September 18, 2026, the Governing Body extended the same conscience-based principle to those four primary blood components. Jehovah’s Witnesses may now decide individually whether to accept donor red cells, white cells, plasma, or platelets, while transfusion of whole blood from another person remains prohibited. Witnesses may also decide whether to donate blood when it is intended to provide components or fractions for use by others.²˒³ Together, the March and September revisions represent a substantial restructuring of Jehovah’s Witness medical policy.

AJWRB welcomes changes that increase patient choice and expand access to medically appropriate treatment. For many Jehovah’s Witnesses, the 2026 revisions provide options that were previously regarded as religiously impermissible. At the same time, rapid changes in organizational guidance create new ethical and practical questions. Clinicians may encounter patients whose understanding of current policy is incomplete, advance directives created under former prohibitions, or official and institutional materials that have not yet been updated.

This article originally focused on the March 2026 PAD revision and the questions it raised concerning informed consent, access to autologous blood collection, advance directives, organizational accountability, and voluntariness. The September 18 revision broadens that analysis. The article now considers the March change within the larger 2026 transformation of Jehovah’s Witness blood policy, including the abandonment of the former categorical prohibition on the four primary blood components, continuing geographic disparities in access to blood-conservation options, the need to reassess older medical directives, and the importance of determining each patient’s contemporaneous treatment preferences. The purpose is not to challenge sincerely held religious convictions, but to examine how evolving organizational guidance affects informed consent, patient autonomy, and clinical practice.

September 20, 2026 Snapshot: Detailed Clinician-Facing Guidance Still Reflected Earlier Policy

AJWRB verified on September 20, 2026 that some detailed clinician-facing materials on JW.org still reflected earlier blood-policy classifications. The page Religious and Ethical Position on Medical Therapy and Related Matters continued to state that Jehovah’s Witnesses do not accept preoperative autologous blood donation and continued to classify donor red blood cells, white blood cells, platelets, and plasma as refused. A separate Bioethics and Law resource likewise continued to describe those treatments as religiously prohibited.

These materials had not yet caught up with the March 20, 2026 reclassification of a patient’s own blood as a matter of individual conscience or the September 18 extension of the same conscience-based principle to the four primary blood components. Although JW.org had begun updating other medical resources, clinicians consulting different official materials during this transitional period could therefore encounter materially different descriptions of current policy.

This illustrates what AJWRB describes as an information-currency problem: information material to a medical decision may remain accurate to an earlier policy while no longer reflecting the organization’s current guidance. In clinical practice, outdated information may influence patients, families, healthcare agents, or clinicians even after the underlying rule has changed. This is one reason treatment preferences should be confirmed directly with the individual patient rather than inferred from generalized or previously published descriptions of Jehovah’s Witness policy.

This dated snapshot documents information available to clinicians on September 20, 2026 and should not be interpreted as a statement about subsequent JW.org guidance.

Figure 1. JW.org clinician-facing guidance as displayed on September 18, 2026, showing preoperative autologous blood collection and storage for later reinfusion as refused. This figure documents guidance available during the 2026 policy transition and should not be interpreted as necessarily representing subsequent JW.org guidance.[8]

A separate JW.org resource for healthcare professionals, Bioethics and Law, was likewise verified on September 20, 2026 as still reflecting earlier blood-policy classifications, including treatment of preoperative autologous blood deposit and the four primary blood components as prohibited.[9] Taken together, these materials document a period during the 2026 policy transition in which official clinician-facing resources did not consistently reflect the organization’s most recent guidance.

This discrepancy illustrates an information-currency problem: information may accurately describe an earlier religious policy while no longer representing the guidance under which a patient is currently making medical decisions. The clinical significance extends beyond these particular webpages. Patients, healthcare agents, and clinicians may continue to rely on older charts, directives, or educational materials after the underlying policy has changed. Current treatment preferences should therefore be established directly with the individual patient rather than inferred from generalized or previously published descriptions of Jehovah’s Witness blood policy.

1. The Doctrinal Pivot: From “Prohibition” to “Personal Conscience”

For decades, Jehovah’s Witness teaching treated blood removed from the body as retaining a sacred status and, consistent with the organization’s interpretation of biblical passages concerning blood, generally required that it be discarded rather than stored for later medical use.[2] Consequently, preoperative autologous donation (PAD)—the collection and storage of a patient’s own blood before surgery for later reinfusion—was regarded as religiously unacceptable. As recently as 2021, official organizational literature stated that donating one’s own blood for later use was “not acceptable for Christians.”[3]

The March 2026 revision represented a significant departure from that position. In Governing Body Update #2, the Governing Body stated:

“The Bible does not comment on the use of a person’s own blood in medical and surgical care… This includes whether to allow his own blood to be removed, stored, and then given back to him.” [1]

By reclassifying PAD and other uses of a patient’s own blood as matters of individual conscience rather than organizational prohibition, the revised guidance changed the framework through which Jehovah’s Witnesses could evaluate these medical interventions. Practices formerly presented as religiously impermissible could now be accepted or refused according to the individual member’s conscience.

The significance of this change became clearer six months later. On September 18, 2026, the Governing Body extended the same conscience-based principle to red blood cells, white blood cells, plasma, and platelets obtained from another person.[7] Whole-blood transfusion from another person remains prohibited, but the four primary components—like blood fractions and the medical use of a patient’s own blood—are now matters for individual decision.

From a bioethical perspective, the two 2026 revisions demonstrate that organizational guidance governing high-stakes medical decisions can change substantially, including rules previously presented as religious prohibitions. For clinicians, this underscores the importance of establishing each patient’s current understanding and treatment preferences rather than assuming that long-standing policies remain unchanged or that all Jehovah’s Witness patients share the same choices.

AJWRB welcomes this expansion of individual choice. At the same time, the rapid transition from categorical prohibition to personal conscience raises broader questions concerning information currency, informed consent, advance directives, doctrinal evolution, and institutional accountability. These questions extend beyond PAD itself and are central to understanding the clinical implications of the 2026 policy changes.

2. The Medical Framework After the 2026 Revisions

Understanding the significance of the 2026 changes requires placing them within the broader evolution of Jehovah’s Witness blood policy. For many years, the organization distinguished between whole blood and four “primary” blood components—red blood cells, white blood cells, platelets, and plasma—which were prohibited, and smaller blood fractions, which individual members could accept or refuse as matters of conscience.[4] The March 2026 revision altered another longstanding rule by making the medical use of a patient’s own blood, including preoperative collection and storage, an individual decision.[1]

On September 18, 2026, that framework changed more substantially. The Governing Body announced that the same principle of personal decision-making now applies to red blood cells, white blood cells, plasma, and platelets obtained from another person.[7] Jehovah’s Witnesses may therefore accept or refuse any of those components according to individual conscience. Transfusion of whole blood from another person remains prohibited. Blood fractions continue to be matters of personal decision, as does the medical use of a patient’s own blood. Witnesses may also decide whether to donate blood when the stated purpose is to provide components or fractions for use by others.[7]

The resulting clinical framework differs substantially from the one that governed Jehovah’s Witness care for decades. A patient’s religious affiliation no longer predicts whether red cells, plasma, platelets, white cells, blood fractions, or autologous procedures will be accepted. Two Jehovah’s Witness patients facing the same clinical circumstances may therefore make quite different treatment choices while each remains within current organizational guidance.

This change also alters the ethical questions raised by the former component-versus-fraction distinction. Earlier commentary often focused on whether it was medically or conceptually coherent to prohibit the four primary components while permitting numerous products derived from them.[5] That historical debate remains relevant to understanding the development of the policy, but it no longer accurately describes the principal clinical problem. The more immediate issue is now whether patients and clinicians have current, individualized information about the choices that organizational policy leaves to personal conscience.

This is particularly important during a period of rapid doctrinal transition. Patients may have learned the former rules over many years, may possess advance directives drafted when red cells, white cells, plasma, platelets, or stored autologous blood were categorically refused, or may encounter educational materials that reflect earlier policy. Conversely, organizational permission does not imply that an individual patient wishes to receive any particular component or procedure. A Jehovah’s Witness may continue to refuse one, several, or all of these treatments for religious, medical, or personal reasons.

For clinicians, the practical consequence is straightforward: treatment choices should be established with the individual patient rather than inferred from a general designation such as “Jehovah’s Witness” or “no blood.” Discussions should identify which specific components, fractions, and autologous procedures the patient accepts or refuses, confirm that the patient understands the available options, and document those preferences clearly. Where clinically feasible, important treatment preferences should be elicited privately so that the patient can express them without unnecessary interpersonal pressure.

From AJWRB’s perspective, the March and September 2026 revisions represent a meaningful expansion of individual choice. They also illustrate how rapidly an established religious medical framework can change. The resulting challenges now concern not only doctrinal development but also information currency, informed consent, the interpretation of legacy advance directives, and the need for clinicians to identify each patient’s contemporaneous preferences.

3. Bioethical Implications and Healthcare System Considerations

The 2026 revisions expand the range of treatment options available to Jehovah’s Witness patients. Their practical benefits, however, will vary according to the patient’s individual choices, clinical circumstances, healthcare infrastructure, and geographic location.

Unequal Access to Autologous Blood Programs

Preoperative autologous blood donation (PAD) generally requires a healthcare system with the capacity to collect, process, store, track, and safely reinfuse a patient’s blood. Such services may be unavailable or limited in resource-constrained settings. Consequently, the practical value of the March 2026 reclassification of PAD will not be the same for all patients.

The September 18 revision changes the ethical context of this disparity. Lack of access to PAD no longer means that donor red cells, white cells, plasma, or platelets are categorically unavailable on religious grounds; each of those components is now a matter of individual conscience.[7] Nevertheless, access to autologous programs remains important for patients who prefer the use of their own blood or who personally continue to refuse donor components. Two Witness patients with identical medical needs may therefore have materially different treatment options depending on both their individual preferences and the resources available where they receive care.

PAD is also unsuitable or impractical for some patients. Individuals with significant anemia, chronic illness, malnutrition, insufficient time before surgery, or urgent surgical needs may be unable to donate an adequate volume of blood in advance. For these patients, the March revision may offer limited practical benefit even though it expands the range of religiously permissible choices.

Implications for Healthcare Delivery

Autologous blood programs require additional institutional resources. Hospitals offering PAD must maintain systems for patient assessment, collection, labeling, storage, transport, traceability, and reinfusion to ensure that each unit is returned only to the original donor. Because autologous units generally cannot be transferred to other patients if unused, wastage may also be greater than with standard blood inventories.[6]

These operational realities remain relevant, but the September revision changes how healthcare institutions should approach Jehovah’s Witness care. Hospitals should not assume solely from religious affiliation that every Witness patient requires a completely bloodless pathway or that donor components are unavailable. Some patients may accept red cells, plasma, platelets, or white cells; others may refuse some or all of them. Appropriate planning therefore depends on documenting the individual patient’s actual choices rather than applying a uniform institutional protocol based on the former policy.

From a broader bioethical perspective, the rapid succession of the March and September 2026 changes demonstrates that organizational medical guidance can affect not only individual treatment decisions but also the resources and pathways healthcare systems develop to accommodate them. Continued communication among patients, clinicians, ethics professionals, healthcare administrators, and religious-support services is important, but the governing clinical principle should remain patient-specific: medically appropriate options should be discussed without assuming acceptance or refusal on the basis of religious affiliation alone.

4. Institutional Accountability and the Ethics of Doctrinal Change

The March and September 2026 revisions raise questions that extend beyond clinical practice and into the ethics of institutional decision-making. When an organization substantially revises long-standing medical guidance affecting potentially life-saving treatment, it is reasonable to consider how earlier policies, subsequent changes, and communication of those changes should be understood.

For decades, Jehovah’s Witness patients made medical decisions within an organizational framework that treated PAD and several major blood-related interventions as religiously impermissible.[2–4] In March 2026, the use of a patient’s own blood was moved into the realm of individual conscience.[1] Six months later, red blood cells, white blood cells, plasma, and platelets were likewise reclassified as personal decisions.[7] Religious organizations may reconsider and refine doctrinal interpretations, but changes involving high-stakes medical decisions inevitably invite reflection on the consequences of guidance that previously governed members’ choices.

One of the most difficult ethical questions concerns individuals who made irreversible medical decisions under the former policy. For some Jehovah’s Witness families, this question is not theoretical. Patients may have died or experienced serious medical outcomes after declining treatments they understood to be religiously prohibited at the time. Subsequent reclassification does not establish what the outcome would have been in any individual case, nor does it by itself assign legal or moral responsibility. It does, however, make the historical consequences of changing medical doctrine ethically relevant.

The present policy changes do not automatically establish that every earlier refusal was uninformed or that patients would have chosen differently had current guidance existed. Many patients may have independently preferred to avoid transfusion regardless of organizational requirements. The ethical concern is narrower: when institutional guidance influences high-stakes decisions, transparency about significant changes helps current patients, clinicians, and affected families understand both the previous framework and the options now available.

Prospective accountability is equally important. Moving additional treatments into the realm of personal conscience increases the number of decisions that must genuinely be made by the individual patient. That shift places particular importance on accurate and timely communication, current educational materials, confidential preference elicitation, and advance directives that reflect the patient’s present wishes rather than superseded organizational rules.

This is where the principle of information currency becomes especially important. A formal policy may change immediately, while older directives, charts, educational materials, institutional routines, and patient understanding may persist. An expansion of religiously permissible options cannot fully support patient autonomy unless patients and clinicians have access to information that accurately reflects the current policy.

These questions are not unique to Jehovah’s Witnesses. They illustrate a broader challenge in bioethics: how should institutions communicate and account for evolving normative guidance when earlier rules have influenced consequential medical decisions? The 2026 revisions provide a contemporary case study in the relationship between institutional authority, changing doctrine, informed consent, and patient autonomy.

From AJWRB’s perspective, the 2026 changes represent a welcome expansion of individual conscience. They also demonstrate that medical-policy changes do not occur in a historical vacuum. They become part of the lived experience of patients and families who made consequential decisions under earlier guidance. Recognizing that history with accuracy, compassion, and transparency is consistent with the broader bioethical commitments to respect for persons, informed decision-making, and institutional accountability.

The Human Cost of the Former PAD Prohibition

5. Updating Advance Directives After the 2026 Blood-Policy Changes

One important consequence of the March and September 2026 revisions is that many existing Jehovah’s Witness advance medical directives were completed under a substantially different organizational blood policy. Older documents may contain categorical refusals of preoperative autologous blood donation, red blood cells, white blood cells, plasma, or platelets because those treatments were religiously prohibited when the directive was executed.[1,7]

The policy changes do not automatically invalidate those directives, nor do they establish that a patient now wishes to accept a treatment that was previously refused. Religious permission and patient consent are separate questions. A Jehovah’s Witness who understands that a component or procedure is now a matter of personal conscience may still choose to refuse it for religious, medical, or personal reasons.

For patients who retain decision-making capacity, the 2026 changes provide an important opportunity to review existing directives and ensure that written instructions still reflect their current treatment preferences. Review should extend beyond PAD to the four primary blood components, blood fractions, autologous procedures, and other blood-related interventions for which individual choice is now central.

The organization has announced that an updated medical directive will be made available.[10] During the transition, Jehovah’s Witnesses have also been advised that they may document their current wishes through legally recognized forms, documents, or procedures available in their jurisdiction and may ask hospitals and healthcare providers to record those wishes in advance.[11]

For clinicians, the appropriate approach depends in part on the patient’s capacity. When the patient can participate in decision-making, current preferences should be confirmed directly and documented specifically rather than inferred from an older “No Blood” designation. A capable patient’s present informed decision should guide care.

When the patient lacks decision-making capacity, however, an older directive should not be disregarded merely because organizational policy has changed. Its wording, legal status, date of execution, applicability to the treatment under consideration, and any reliable evidence of the patient’s later preferences should be considered under applicable law. A healthcare agent or surrogate may provide additional evidence of the patient’s values and wishes but should not substitute his or her own religious preferences for those of the patient. Where genuine interpretive uncertainty remains and circumstances permit, consultation with clinical ethics or legal counsel may be appropriate.

This illustrates a broader principle of informed consent and information currency. Durable medical instructions may remain in force after the normative framework that helped shape them has changed. The ethical task is therefore neither to assume that an older refusal remains unchanged nor to presume that the patient would now accept treatment, but to determine as reliably as possible what the patient presently chooses—or, if incapacitated, what the patient would have chosen.

From AJWRB’s perspective, the 2026 revisions underscore the importance of periodic review of advance medical directives whenever significant medical, personal, or religious circumstances change. Keeping written instructions aligned with a patient’s current understanding and preferences strengthens autonomy and reduces the risk that emergency treatment decisions will inadvertently implement a superseded organizational rule rather than the patient’s own wishes.

6. Mandated Shunning, Voluntariness, and the Integrity of Informed Consent

The September 18, 2026 revision materially changes the relationship between blood-treatment decisions and congregational discipline. Under current organizational guidance, each Jehovah’s Witness decides personally whether to accept or refuse red blood cells, white blood cells, plasma, platelets, or blood fractions, and the congregation is not to become involved in those decisions.[7,10] Accordingly, acceptance of one or more of those components should no longer be described as conduct that, by itself, exposes a baptized member to congregational action. Transfusion of whole blood from another person remains prohibited.[7,10]

The broader question of voluntariness nevertheless remains clinically relevant. The practice of shunning documented in the literature can involve substantial loss of family relationships, friendships, congregation ties, and social support following disciplinary separation or disaffiliation.[13,14] The existence of such potential relational consequences does not establish coercion or undue influence in any particular medical decision, but it may form part of the decisional environment for some patients.

For many Jehovah’s Witnesses, religious belief, family relationships, and community identity reinforce one another in ways that are fully compatible with autonomous choice. A patient may sincerely refuse whole blood, one or more blood components, or any other treatment because that decision reflects the patient’s own religious convictions and values. Such decisions deserve the same respect afforded to other informed choices made by a competent adult.

At the same time, clinicians should remain attentive when a patient expresses fear of relational loss, disciplinary consequences, or community reaction as a material factor in a high-stakes medical decision. The relevant ethical question is not whether the patient belongs to a close-knit religious community, but whether the individual understands the available options, presently endorses the decision as his or her own, and can express treatment preferences without interpersonal pressure that materially constrains choice.

For healthcare professionals, this supports the use of confidential, non-directive conversations in which important treatment preferences can be discussed privately. Such conversations are not intended to challenge religious belief or persuade a patient to accept treatment. Their purpose is to establish the patient’s own informed preferences and to distinguish genuine personal conviction from unresolved informational uncertainty or concerns about social consequences.

Current Jehovah’s Witness guidance itself now states that there is usually no need for members to discuss personal medical decisions with individuals other than the healthcare agents named on their medical directive. It also states that, when requested by the patient, Hospital Liaison Committees may provide support, assist in locating physicians, and keep the patient’s decisions confidential.[10] These provisions are compatible with the clinical goal of protecting private preference elicitation while allowing patients to obtain religious information or support from sources they trust.

The broader ethical principle extends beyond Jehovah’s Witnesses. Whenever high-stakes medical decisions occur within communities that combine evolving normative guidance with meaningful relational consequences for dissent, clinicians should attend both to information currency and to voluntariness. Respect for religious liberty and protection of autonomous decision-making are complementary rather than competing ethical commitments.

From AJWRB’s perspective, the 2026 revisions represent meaningful progress toward expanding individual conscience. Their full benefit will be realized when patients have accurate current information, privacy in which to express their preferences, and confidence that decisions concerning treatments now classified as matters of conscience genuinely belong to them.

Conclusion

Taken together, the March and September 2026 revisions represent one of the most significant transformations of Jehovah’s Witness blood policy in decades. The March change moved the medical use of a patient’s own blood, including preoperative collection and storage, from categorical prohibition to individual conscience.[1] Six months later, the same principle was extended to red blood cells, white blood cells, plasma, and platelets obtained from another person, as well as to blood donation for the purpose of providing components or fractions.[7,10] Whole-blood transfusion from another person remains prohibited.

These changes substantially expand the range of treatment choices available to Jehovah’s Witness patients. They do not, however, establish that any particular patient will accept a component or procedure that was formerly prohibited. Religious permission is not patient consent. Some Witnesses may accept several newly permissible options, while others may continue to refuse some or all of them on religious, medical, or personal grounds.

The revisions also create important transitional challenges. Patients may possess advance directives completed under earlier rules, may have learned former prohibitions over many years, or may encounter medical and organizational materials that have not yet been brought into alignment with current policy. The documented divergence among official clinician-facing materials during 2026 illustrates the importance of information currency: high-stakes treatment decisions may be influenced by information that accurately described an earlier rule but no longer reflects the organization’s current guidance.

For clinicians, the practical lesson is straightforward. Identification as one of Jehovah’s Witnesses should no longer be treated as synonymous with refusal of red cells, plasma, platelets, white cells, blood fractions, or autologous procedures. Treatment preferences should be established with the individual patient, discussed privately when clinically important, and documented with sufficient specificity to guide care. Legacy advance directives should be respected but interpreted carefully when subsequent changes in religious guidance create genuine uncertainty about their continuing applicability.

The human consequences of doctrinal change also remain relevant. Patients and families made consequential medical decisions under policies that differed from those now in effect. A later change does not establish what any individual would have chosen under different circumstances or what a medical outcome would have been. It does, however, underscore the importance of transparency, accurate communication, and institutional recognition that medical rules capable of affecting life-and-death decisions can evolve.

AJWRB welcomes the expansion of individual conscience represented by the 2026 changes. The enduring bioethical objective is not to encourage acceptance or refusal of blood treatment, but to ensure that each patient can make decisions on the basis of current information, meaningful voluntariness, and personal values. Respect for religious liberty is strongest when it protects the individual’s right to decide.

References

[1] Jehovah’s Witnesses. 2026 Governing Body Update #2. JW.org. March 20, 2026.

[2] Watchtower Bible and Tract Society. Blood, Medicine and the Law of God. 1961:14–15.

[3] Watchtower Bible and Tract Society. Enjoy Life Forever!—An Interactive Bible Course. Endnote 3. 2021.

[4] Watchtower Bible and Tract Society. “Questions From Readers.” The Watchtower. October 15, 2000; and June 15, 2004.

[5] Alliance for Jehovah’s Witness Research and Bioethics. “The Hemoglobin Paradox.” AJWRB. 2024.

[6] Rosenblatt MA, Cantos EM Jr, Mohandas K. Intraoperative hemodilution is more cost-effective than preoperative autologous donation for patients undergoing procedures associated with a low risk for transfusion. J Clin Anesth. 1997;9(1):26–29. doi:10.1016/S0952-8180(96)00213-9.

[7] Jehovah’s Witnesses. 2026 Governing Body Update #6. JW.org. September 18, 2026. Accessed September 20, 2026.

[8] Jehovah’s Witnesses. Religious and Ethical Position on Medical Therapy and Related Matters. JW.org Medical Library. Accessed September 20, 2026.

[9] Jehovah’s Witnesses. Bioethics and Law. JW.org Medical Library. Accessed September 20, 2026.

[10] Jehovah’s Witnesses. How Do Jehovah’s Witnesses Show Respect for Life?. JW.org. September 2026. Accessed September 20, 2026.

[11] Jehovah’s Witnesses. September 18, 2026 congregation announcement concerning Governing Body Update #6 and interim medical-directive guidance. Copy obtained by AJWRB.

[12] Jehovah’s Witnesses. Advance Decision to Refuse Specified Medical Treatment (DPA). Standard form, 2023 revision.

[13] Grendele WA, Bapir-Tardy S, Flax M. Experiencing religious shunning: insights into the journey from being a member to leaving the Jehovah’s Witnesses community. Pastoral Psychology. 2024;73:43–61. doi:10.1007/s11089-023-01074-y.

[14] Ransom HJ, Monk RL, Heim D. Grieving the living: the social death of former Jehovah’s Witnesses. Journal of Religion and Health. 2022;61(3):2458–2480. doi:10.1007/s10943-020-01156-8.

A Note on Qualitative Patient Narratives:

The bioethical analysis and clinical guidance presented in the text above are intended for professional review. However, AJWRB recognizes that behind every clinical discussion is a profound personal impact. The comment forum below is maintained as an open space for current members, former members, and their families to share their lived experiences regarding Jehovah’s Witness blood refusal and informed consent. Please note that while these community-generated narratives are anecdotal and remain strictly distinct from peer-reviewed clinical data, we preserve them as vital qualitative perspectives on the real-world consequences of institutional medical directives.